← FDA DRUG APPROVALS

FDA ANDA · ANDA091305

NAPROXEN

Sponsor: INVAGEN PHARMS

APPLICATION
ANDA091305
TYPE
ANDA
ORIGINAL APPROVAL
2011-08-24
LATEST ACTION
2019-10-25
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

NAPROXENDiscontinued
NAPROXEN 375MG · TABLET · ORAL
NAPROXENDiscontinued
NAPROXEN 500MG · TABLET · ORAL
NAPROXENDiscontinued
NAPROXEN 250MG · TABLET · ORAL

Approval history

2019-10-25Labeling · Supplement 13 · standardAP
2019-10-25Labeling · Supplement 11 · standardAP
2016-08-03Labeling · Supplement 6 · standardAP
2016-08-03Labeling · Supplement 5 · standardAP
2011-08-24OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →